While targeted therapies have been effective at treating the advanced states of several adult cancers, the development of targeted therapy for treating HR-NB is still in the very early stages —primarily because the hallmark genomic aberration of HR-NB, MYCN amplification, has been difficult to target [5]. Here, MYCN is linked to neuroblastoma.